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Abstract
Evidence informed practice  is  a key component  of public  health  and the focus of 
much discussion, of which the nature of evidence and how it is best gathered and 
appraised has formed a large part.   Prospective registration of trials  is  now a key 
component  of  rigor  and quality  in  clinical  research  and has  been supported  at  an 
international level through the WHO International Clinical Trials Registry Program. 
This paper discusses the scope and benefits of trial registration in clinical research, 
including  greater  transparency and reduced  publication  bias.  It  then  considers  the 
potential  for  a  Prospective  Public  Health  Intervention  Studies  Register  (PPHISR) 
specific to the needs of public health and aspects to be included in such a register. It is 
argued that this initiative has the potential to facilitate increased global cooperation 
and efficiency in the production of high quality evidence and ultimately in improved 
health outcomes for populations.
Background
The  importance  of  evidence  informed  practice  in  public  health  practice  is  well 
recognised1-3. Much of this discussion has focused on the nature of evidence within 
public health and on appropriate methods of gathering and appraising such evidence4, 
5.  Knowledge  synthesis,  translation  and  exchange  between  research,  policy  and 
practice is also a growing area in public health, with many now exploring the most 
appropriate ways of facilitating and supporting these processes1, 2.  Evidence informed 
practice helps to identify the potential best buys for health across the broad spectrum 
of health services from both up stream and down stream perspectives. 
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Within clinical research a key mechanism for ensuring rigour and quality, and to aid 
the production of unbiased systematic reviews and meta-analyses, is the prospective 
registration of clinical trials3. Without prospective registration there is a strong danger 
that  disappointing  findings  will  disappear  without  trace,  thus  distorting  publicly 
available research evidence. Additionally,  trials may be unnecessarily duplicated or 
subject to less rigorous ethical  and scientific  critique3.  This paper will  explore the 
scope and benefits of clinical trial registration before then considering the potential 
for a Prospective Public Health Intervention Studies Register (PPHISR) specific to the 
needs of public health. 
Importance of Registering Clinical Trials
The  importance  of  registering  clinical  trials  is  increasingly  recognised  at  an 
international  level with the World Health Organisation approving the International 
Clinical  Trials  Registry  Program in  20059,  10.  Recognised  benefits  of  clinical  trial 
registration  include  greater  transparency  regarding  studies  in  progress  which  aids 
communication  between  researchers  and  reduces  unnecessary  replication,  reduced 
publication bias, and improved recruitment as the public is better informed about the 
conduct and purpose of trials4. With these benefits in mind, the WHO program was 
established  to  provide  leadership  in  the  development  of  international  norms  and 
standards for clinical  trial  registration and reporting.  Its  intent  is not to develop a 
WHO administered trial register, but rather to establish a global network of registers 
that meet internationally acceptable criteria and to define minimum standards for the 
reporting of trial results5. In effect, it  will allow interested parties to access a web 
based  portal  enabling  all  registered  trials  to  be  searched  at  a  global  level  5.The 
importance of trial registers within health research is internationally recognised3, 6-8, as 
demonstrated by a policy implemented by the International Committee of Medical 
Journal Editors in 20059. From 1 July 2005 a number of prestigious scientific journals 
now  only  publish  intervention  trial  results  if  trials  were  registered  in  a  publicly 
accessible register at their commencement9. 
Within  evidence  based  health  research  and  practice,  clinical  trials  are  considered 
foundational to decision making3, 5. Accordingly, access to information about research 
is  critical  to  researchers,  practitioners  and  policy  makers,  as  well  as  health  care 
consumers3, 5. Prospective registration of clinical trials is considered important for a 
number  of  key  reasons,  a  number  of  which  are  encompassed  by  the  notion  of 
transparency in  health  research11,  12,  15,  16.  According to  WHO, transparency in  this 
context refers to ‘public knowledge about what research questions have been asked, 
what has been learned, and what has happened in clinical trials of health interventions 
in humans’ (p.1) 10.
Registration  of  trials  in  a  publicly  accessible  register  provides  full  information  to 
researchers, practitioners, decision makers and consumers from the inception of the 
trial. This ensures a trial is public knowledge well before final results are published in 
a scientific journal 3. A number of benefits result, including subjecting trials to greater 
scrutiny and review by those outside of the trial and fulfilling ethical responsibilities 
to participants through the provision of complete information regarding trial conduct, 
potentially  reducing  harm  from  poorly  conducted  or  unethical  trials5,  11.  This  is 
particularly important with the increasing trend of conducting early clinical trials in 
developing  countries  where  regulation  and  monitoring  is  often  poor4.  Greater 
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knowledge of ongoing trials also minimises unnecessary duplication of research and 
assists the identification of gaps in knowledge leading to better use of research funds 
and sharing of methods and tools8, 10,  15,  17. It also improves the accuracy of research 
conducted  on research  processes,  and increases  the  quality  of  systematic  reviews, 
meta-analyses and other forms of knowledge synthesis, translation and exchange8, 11-13. 
Trial registers also increase transparency through reduction of publication bias8, 17, the 
publication or non-publication of research findings according to the nature of results 
12. In their review of types of reporting biases found in medical research Egger et al. 
found that the majority of studies published in medical and social science research 
report significant results or a beneficial treatment effect, while many studies that find 
no effect remain unpublished12, 14. They identify a number of papers which found that 
the  delay  in  publication  of  trials  from  the  initial  time  of  approval  by  an  ethics 
committee was much greater  for studies  with null  results  than those with positive 
findings12. In addition, positive effects of trials were more likely to be published in the 
English language rather than in the original authors’ native language11,  12. Selective 
publication  where  only  some,  usually  positive,  trial  outcomes  are  reported,  and 
multiple  reporting of studies also bias the literature and can be alleviated through 
greater transparency and universal registration of studies11. 
The  International  Clinical  Trials  Registry  Platform  has  engaged  in  extensive 
consultation  with  key  stakeholders  in  order  to  reach  agreement  on  20  items  for 
minimum  trial  registration  data4,  7.  Part  of  this  process  has  involved  discussion 
regarding the timing of trial  registration,  and whether this  should include early or 
phase 1 trials, as well as whether trial registration information should be completely 
disclosed at the time of registration4. Despite the clear benefits that prospective trials 
registers  have  with  regards  to  improved  transparency,  debate  has  centred  around 
concerns that transparency needs to be balanced with the need to protect academic or 
commercial  advantage  which  may  be  compromised  by  early  registration4,  10.  For 
example,  early  publication  of  new  and  emerging  interventions  may  increase  the 
possibility of other parties inappropriately benefiting from the original researchers’ 
efforts  so  reducing  potential  for  commercial  or  academic  gains.  The  incentive  to 
compete or innovate may be reduced by this  early openness. However,  Sim et al. 
report that there is no evidence to support this notion, and conversely openness may 
actually  enhance  innovation  through  enhanced  communication  and  collaboration 
between  researchers  and  other  key  stakeholders4.  Additionally,  the  rights  of  trial 
participants  are  far  more  important  than  commercial  or  career  interests4,  10.  As  a 
consequence,  the  two  principles  identified  by  WHO  as  foundational  to  trial 
registration are that all  intervention trials,  including early phase studies, should be 
registered, and secondly, that at the time of registration all of the 20-item minimum 
dataset components must be disclosed4, 7.
Aspects of the registration process still need to be defined, including the possibility of 
broadening the minimum dataset to include further detail7. For example, the proposed 
minimum  dataset  does  not  include  a  number  of  items  proposed  by  the  Ottawa 
Statement on Principles for Trial Registration, produced by an international group of 
stakeholders  interested  in  trial  registration,  including  systematic  reviewers  and 
representatives from the pharmaceutical industry8. Undoubtedly the make-up of the 
WHO minimum dataset will be an issue for ongoing debate and refinement.
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Relevance to Public Health
As evidence is critically important to all areas of public health is well recognised15, 
the arguments for the arguments for trials registers also apply to health promotion and 
public  health  research.  A  foundational  part  of  the  production  and  utilisation  of 
evidence is the conduct of high quality primary research and evaluation together with 
research synthesis activities such as the production of systematic reviews and health 
technology  assessments.   As  with  clinical  medical  research,  the  prospective 
registration of public health intervention studies is a vital part, in fact a key first step,  
in  the  conduct  of  both  primary  research  and research  synthesis  and  hence  in  the 
production of rigorous evidence.
Public  health  randomised  controlled  trials  can  be  registered  within  clinical  trial 
registers  currently available.  However,  the nature of research and evidence within 
public health and health promotion means that often other study designs evaluating 
complex community interventions which are generally complex and multi-faceted are 
vital for informing the evidence base15-21. The notion of complexity is now recognised 
within  the  public  health  evidence  arena  as  greatly  effecting  design,  measurement, 
analysis and use of findings from evaluations of community interventions15. Rigorous 
randomised controlled trials are often insufficient and can be particularly challenging 
for evaluating interventions that are more complex and community based rather than 
simple  interventions  of single issues or single health  promotion objectives1,  3.  The 
importance of utilising multiple methods and data sources, including qualitative and 
quantitative,  experimental  and  observational  research,  in  developing  public  health 
evidence is now well recognised17, 18.
This emphasis on multiple methods in public health evidence reflects  the growing 
awareness  of  the  importance  of  contextual,  including  social,  political  and 
organisational, factors in which an intervention is conducted, to evaluation design and 
interpretation of findings19, 22. Consideration of the impact of interventions on health 
equity, such as differences in outcomes for groups within the intervention population, 
is also viewed as important when conducting evaluations and systematic reviews in 
health promotion and public health. This recognition of the need to focus on health 
inequalities provides added weight to the argument for multiple methods in order to 
ensure that appropriate data is collected in order to build a comprehensive evidence 
base23.
In the light of these arguments, it needs to be asked whether clinical trial registries are 
appropriate to the unique and complex needs of public health research and evaluation. 
The public health evaluation literature supports the need not for a public health trials  
registers,  but  for  a  prospective  intervention  studies register  specific  to  the 
requirements  of  public  health  research  given  their  relevance  and  importance  to 
evidence informed practice.
As  with  clinical  research,  surely  public  health  would  benefit  from  greater 
transparency and accountability  regarding the research currently being undertaken. 
Many resources are being directed into current public health ‘hot topics’ such as child 
obesity and mental health promotion, and a prospective trial register would assist in 
the  reduction  of  unnecessary  duplication  of  studies  and  hence  the  better  use  of 
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research  funds.  Better  dissemination  and  synthesis  of  findings  through  systematic 
reviews and meta-analyses would also be promoted, as would the identification of 
gaps  in  the  evidence.  Many  public  health  interventions  work  with  vulnerable  or 
disadvantaged groups such as children, those experiencing poverty, unemployment, or 
other forms of marginalisation. All of these groups would benefit from the increased 
protection from potential harm caused by poorly conducted intervention studies which 
would be gained from increased transparency and accountability.  
The  broader  inclusion  of  design  methodology  for  public  health  may  provide  a 
challenge as to whether a study is appropriate for the registry. For example, a health 
agency may provide a health promotion initiative to one area and not to another, and 
in the process undertake a robust evaluation utilising the un-serviced areas of their 
jurisdiction as the control. The establishment of a registry will require an agreement 
as to at what point a study emerges in the delivery of a previously unevaluated health 
intervention. Conceivably a grey area will occur where under-reporting of potentially 
applicable study designs occurs. Capturing whether or not the study received approval 
from a human ethics committee will be important in assessing the prospective nature 
of the design.
More work is needed to identify the particular aspects to be included in a Prospective 
Public Health Intervention Studies Register. This will need to be developed over time 
in  consultation  with  key  stakeholders  including  researchers,  policy  makers, 
practitioners  and  consumers.  However,  ensuring  that  a  public  health  intervention 
studies  register  is  consistent  with  the  WHO  proposal  is  important  to  allow  for 
consistency and international access 10. Table 1 outlines the WHO Trial Registration 
Data  Set,  many  of  which  are  applicable  to  public  health  intervention  studies.  In 
addition, a number of items that we argue should also be included in a public health 
intervention  studies  register  are  included.  Many  of  these  are  informed  by  the 
Cochrane Health Promotion and Public Health Guidelines for conducting systematic 
reviews23 which  have  been  developed  through  the  process  of  identifying  core 
information for decision makers integrated with cutting edge developments in high 
quality intervention development and evaluation design. 
We  believe  that  the  contribution  of  this  proposed  Prospective  Public  Health 
Intervention  Studies  Register  to  the  public  health  evidence  base  would  be 
considerable and ensure that public health research is subject to the same checks and 
balances as clinical research. For example, the public health work program of the UK 
National Institute  of Clinical  Excellence (NICE) has been championing the use of 
public health evidence in population health guidance, and the relationship between 
commissioning,  evaluating  and use of  evidence  would  be  greatly  strengthened by 
increased awareness of what studies are underway or proposed internationally. This 
initiative has the potential to facilitate increased global cooperation and efficiency in 
the production of high quality evidence and ultimately in improved health outcomes 
for populations. 
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New Cochrane reviews and protocols from Issue 2, 2007
New Reviews
• Bicycle helmet legislation for the uptake of helmet use and prevention of head 
injuries
• Contracts between patients and healthcare practitioners for improving patients' 
adherence to treatment, prevention and health promotion activities.
• Effectiveness of brief alcohol interventions in primary care populations
• Electronic mosquito repellents for preventing mosquito bites and malaria infection
• Methods to increase response rates to postal questionnaires
• Screening for abdominal aortic aneurysm
• Wholegrain cereals for coronary heart disease
New protocols
• Alcohol and drug screening of occupational drivers for preventing injury
• Antenatal breastfeeding education for increasing breastfeeding duration (2006 
HPPH Field bursary recipient)
• Educational interventions for the prevention of eye injuries
• Hepatitis B immunization in persons not previously exposed to hepatitis B or with 
unknown exposure status
• Home-based HIV voluntary counselling and testing in developing countries
• Interactive computer-based interventions for sexual health promotion
• Kinship care for the safety, permanency, and well-being of children removed from 
the home for maltreatment
• Methods to influence the completeness of response to self-administered 
questionnaires
• Mono and multifaceted allergen reduction interventions for preventing asthma in 
children at high risk of developing asthma
• One-to-one dietary interventions undertaken in a dental setting for a change in 
dietary behaviour and the prevention of dental caries and erosion
• Social and lifestyle interventions for preventing low birthweight in South Asians
• Supplementary feeding with nutritional education for caregivers for promoting 
growth and development in young children in developing countries
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Table 1 Potential items for a public health intervention studies register
Item WHO Trial Registration Data Set 10 Potential Adaptations for Public  
Health 
1 Primary register and Trial ID# Trial ID#
2 Date of registration in Primary 
Register
Date of registration
3 Secondary ID#s Secondary ID#s
4 Source(s) of Monetary or Material 
Support
Source(s) of Monetary or Material 
Support
5 Primary Sponsor Primary Sponsor
6 Secondary Sponsor(s) Secondary Sponsor(s)
7 Contact for Public Queries Contact for Public Queries
8 Contact for Scientific Queries Contact for Scientific Queries
9 Public Title Public Title
10 Scientific Title Scientific Title
11 Countries of Recruitment Countries of Recruitment
12 Health Condition(s) or Problem(s) 
Studied
Expanded to reflect broader scope of 
public health e.g. population health 
and social outcomes, improvements in 
health equity, reduction in inequalities
13 Intervention(s) (e.g.name, dose, 
duration and control)
Expanded to incorporate wide range of 
interventions, including those that are 
complex and multi-faceted
14 Key Inclusion and Exclusion Criteria Key Inclusion and Exclusion Criteria 
eg. baseline and outcome health 
status/environment/behaviour data, 
health status data, studies which 
comprise intervention and comparison 
groups/data
15 Study Type (e.g. single arm, 
randomized controlled)
Expanded to include a broader range 
of study designs
16 Date of First Enrolment Date of First Enrolment
17 Target Sample Size Target Sample Size
18 Recruitment Status Recruitment Status
19 Primary Outcome(s) Primary Outcome(s)
20 Secondary Outcome(s) Secondary Outcome(s)
21 Program logic or theoretical 
framework
22 Process evaluation methods
23 Resource use assessment and 
Economic impact methods
24 Impact on health inequalities
25 Sustainability considerations
26 Contextual issues (individual, school, 
community, organisational, structural)
27 Approval from a human research 
ethics committee
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